纤维蛋白封闭剂应用于复杂手术止血效果观察

对102例(观察组)复杂手术病人应用纤维蛋白封闭剂止血,与同期同类型手术行常规止血的104例(对照组)进行对比观察.结果观察组止血效果明显优于对照组.提示纤维蛋白封闭剂对创面广泛渗血有迅速止血作用.     

纤维蛋白封闭剂预防硬膜外粘连的实验研究

目的探讨纤维蛋白封闭剂预防术后硬膜外粘连的中长期效果。方法成年健康犬10只。均行L2及L5全椎板切除术,制作椎板缺损模型。随机取5只犬,于L2缺损区喷涂纤维蛋白封闭剂,L5作为空白对照;于另5只犬的L5缺损区喷涂纤维蛋白封闭剂,L2作为空白对照。均在术后6个月处死,取出腰椎进行大体观察、组织学及MRI研究。结果对照组可见大量瘢痕组织增生,硬膜与后方瘢痕组织粘连紧密。纤维蛋白封闭剂组硬膜与瘢痕之间有间隙。无明显粘连。结论纤维蛋白封闭剂中长期防粘连效果是可靠的。     

纤维蛋白胶止血效果的临床研究

目的　观察纤维蛋白胶在普外科手术中的止血效果。方法　将 70例择期手术患者随机分为实验组及对照组 ,每组各 35例。实验组患者肝断面及切口渗血使用纤维蛋白胶止血 ,对照组使用生理盐水 ,并记录每个患者渗血停止时间和渗血量 ,据此计算出单位面积渗血量。结果　实验组渗血停止时间、渗血量、单位面积渗血量均明显少于对照组 (P <0 .0 1和P <0 .0 5 )。结论　纤维蛋白胶用于肝切面及普外科手术切口时 ,具有确切的止血效果。     

纤维蛋白胶在右肝癌切除术中的应用

目的观察纤维蛋白胶在右肝癌切除术中的止血效果。方法对21例右肝癌切除中应用纤维蛋白胶后的止血效果进行观察，并与未用纤维蛋白胶的对照组进行比较。结果使用纤维蛋白胶组术后24h平均失血160ml，对照组术后24h平均失血334ml(P<0.01)。结论纤维蛋白胶在右肝癌切除术中有良好的止血作用。     

纤维蛋白封闭剂是否能降低前列腺癌根治术后即刻漏尿

在华盛顿医院中心，只在1名外科医师所做的前列腺癌根治术后使用纤维蛋白封闭剂，评价其减低术后漏尿的效果。2003年4—11月．32例连续前列腺癌根治术患者，第1组16例（对照）应用Walsh技术进行，第2组16例在尿道膀胱颈吻合口使用纤维蛋白封闭剂。术后每8h测量引流量。在4个护理单元后，对照组81％（13／16）拔掉引流管，而纤维蛋白封闭剂组为100％（16／16）。纤维蛋白封闭剂组总引流量明显少于对照组。     

血凝酶注射液在腭裂整复术中的止血效果分析

目的：观察注射用血凝酶（巴曲亭）在腭裂修复术中的止血效果。方法：回顾性分析单侧完全性腭裂整复术患者180例。随机分为实验组和对照组。实验组应用血凝酶术前10min静脉推注0．5～1U；术后连续静点0．5—1U3天，对照组不用血凝酶。记录术中出血量、手术时间、双侧松弛切口完全止血时间；同时观察患儿出院创口愈合情况等各项指标。结果：血凝酶组患者在术中出血量、手术时间以及双侧松弛切口完全止血时间，创口愈合时间少于对照组。两组出院时创口愈合情况无明显差异。结论：血凝酶注射液在腭裂修复中能够减少术中，术后出血，具有明显的止血效果，安全可靠。     

纤维蛋白原-胶原海绵片在肝手术创面的止血及组织封闭作用的动物实验研究

目的探讨纤维蛋白原鄄胶原海绵片在手术创面的止血性能、封闭创面的效果及在体内降解吸收的状况。方法将SD大鼠20只随机分成实验组和对照组。实验组用纤维蛋白原鄄胶原海绵片进行止血,对照组用明胶海绵片止血。结果在大鼠肝表面的切口,两种止血材料均能即刻止血。纤维蛋白原鄄胶原海绵片与切口粘附紧;而明胶海绵片较易脱落。在大鼠左肝前叶切除术中,纤维蛋白原鄄胶原海绵片组在止血时间及出血量的指标上均优于明胶海绵片组(P<0.05)。组织学检查:创面炎症消退、止血材料降解和促肝细胞再生,实验组均优于对照组。结论纤维蛋白原鄄胶原海绵片能有效地止血,与创面的粘附力强,吸收降解快,且能诱导肝创面肝细胞再生。因而,纤维蛋白原鄄胶原海绵片是一种安全的局部止血、组织封闭和促进细胞再生的生物材料。     

特可靠纤维蛋白胶在肺外科的应用

特可靠纤维蛋白胶在肺外科的应用于长海，孙玉鹗，周乃康，戴为民，李冬１９９２年７～１１月我们为９例肺切除手术病人应用了西德生产的特可靠（ＴａｃｈｏＣｏｍｂ）纤维蛋白胶。其止血、封堵漏气效果良好，同时又不影响肺的膨张，现介绍如下：特可靠是一种网绒状局部止...     

可降解生物止血材料在普通外科手术中的应用观察

目的 观察可降解生物止血材料在普通外科手术中的止血效果及其安全性评估.方法 在2010年3月至2010年12月期间收治的120例普外科手术中,分别应用可吸收止血膜和常规止血方法,对止血时间、术中出血量、术后24h引流量等止血效果进行观测,同时观察生命体征和血、尿常规、肝肾功能等安全性指标,将实验组(可吸收止血膜)和对照组(使用常规止血方法)进行对比,并进行比较分析.结果 使用可吸收止血膜的治疗组对比常规止血的对照组止血效果明显,止血时间平均缩短3s、出血量平均减少30ml、术后24h引流量平均减少50ml(P<0.01),安全性方面,伤口愈合时间、并发症发生率、二次手术病例次等优于对照组,生命体征异常率差异明显(P<0.01).结论可降解生物止血材料(可吸收止血膜)有良好的止血效果,同时安全性良好.     

纤维蛋白封闭剂在颅脑手术中应用的临床研究

纤维蛋白封闭剂(fibrin sealant，FS)又称为纤维蛋白胶(fibringlue，FG)、纤维蛋白组织粘合剂(fibrin tissue adhesive)等。我们将上海利康瑞生物公司研发生产的丰联纤维蛋白封闭剂(丰联FS)应用于颅脑外科手术中，取得了较好的效果，现报告如下。     

Combination of a liquid fibrin sealant with sheet‐type hemostatic agents: Experimental evaluation in partial nephrectomy animal model

Liquid fibrin sealants, together with sheet‐type hemostatic agents, have been used during partial nephrectomies to secure effective hemostasis at the suture site. Using animal kidneys, we investigated which hemostatic agent might adhere most effectively to the renal tissue and serve best as a bolster. Liquid fibrin sealant alone, or in combination with a sheet‐type hemostat, such as collagen, gelatin or oxidized‐cellulose hemostat, was applied to the cut surface of the kidney of anesthetized rabbits, and the differences in the degree of adherence to the kidney and resultant hemostatic efficacy were evaluated. Histological analyses were also carried out to compare the degree of adherence of each of the aforementioned hemostats to the kidney tissue. Fibrin sealant plus the collagen or gelatin hemostat was found to have a stronger hemostatic effect than fibrin sealant applied alone or fibrin sealant plus oxidized‐cellulose hemostat. The histological investigation showed that the fibrin sealant adhered well to kidney tissue when it was applied with the collagen or gelatin hemostat, showing the advantage of combining these two materials for achieving effective hemostasis. Fibrin sealant used in combination with the collagen or gelatin hemostat was the most suitable for obtaining a reinforced hemostatic effect at the suture site in a partial nephrectomy animal model.     

The use of fibrin sealant in urology

PURPOSE: Fibrin sealant has been increasingly applied in various surgical fields, including urological surgery, in the last 2 decades. We determined the safety and efficacy of fibrin sealant in urological surgery and identified areas that need further clinical investigation. MATERIALS AND METHODS: A MEDLINE search of all available literature regarding the use of fibrin sealant was performed. All articles, including experimental animal studies, prospective and retrospective studies, case series and case reports of fibrin sealant for hemostasis and/or other urological applications, were identified and reviewed. RESULTS: Prospective randomized studies in the field of thoracic and trauma surgery show the efficacy and safety of fibrin sealant for hemostasis. Based on these data fibrin sealant has been used successfully for hemostasis during partial nephrectomy and traumatic renal reconstruction. A number of experimental animal studies, case series and case reports show the efficacy of fibrin sealant for ureteral anastomosis, microsurgical vasal anastomosis, fistula repair, circumcision and orchiopexy as well as it use as an adjunct in other areas of reconstruction. CONCLUSIONS: Fibrin sealant is an effective and safe topical agent for controlling surface bleeding during elective and trauma related urological procedures. Using fibrin sealant as an adhesive for reconstruction requires further prospective studies. The introduction of laparoscopic procedures in urology may expand the indications for fibrin sealant as an alternative method of tissue reapproximation. Limiting the routine use of fibrin sealant to procedures with demonstrable benefits is desirable and would lead to a cost saving approach.     

Fibrin sealant in breast surgery

Recent research has investigated the use of fibrin sealant (FS) in axillary lymph-node dissections performed for staging carcinoma of the breast. The majority of complications of axillary dissections in breast surgery stem from the two factors that influence the formation of seromas, hematomas, and lymphedema: the oozing of small transected vessels and the creation of a reservoir due to the removal of tissue. An effective surgical adhesive could improve hemostasis and tissue adherence, thereby decreasing the frequency of these postoperative problems. This paper reviews the use of fibrin sealant in breast surgery to reduce postoperative serous drainage by improving hemostasis and tissue adherence.     

Hemostatic efficacy of two advanced dressings in an aortic hemorrhage model in Swine

BACKGROUND: An effective hemostatic agent capable of stopping severe arterial bleeding and sustaining hemostasis over a prolonged time is required. The U.S. Army recently distributed fibrin sealant (under an Investigational New Drug-approved protocol) and chitosan dressings among deployed medics for treating severe external hemorrhage on the battlefield. The purpose of this study was to evaluate the efficacy of these dressings, as compared with the standard gauze army field dressing, to provide initial and sustained hemostasis up to 96 hours in a lethal uncontrolled arterial hemorrhage model. METHODS: Anesthetized pigs were splenectomized and chronically instrumented for fluid/drug administration and continuous monitoring of vital signs. An infrarenal aortotomy was created using a 4.4-mm aortic hole punch and free bleeding was allowed for 5 seconds. While bleeding profusely, a dressing was applied and pressed into the wound for 4 minutes (occluding the distal flow) and then released. If hemostasis was not obtained, the dressing was replaced with a new one (maximum, two dressings per experiment) with another 4-minute compression. If hemostasis was achieved, the abdomen was closed; the animal was then recovered and monitored up to 96 hours. Initial hemostasis, duration of hemostasis, survival time, blood loss, and other variables were measured. RESULTS: Application of army field dressing (gauze) did not stop the arterial hemorrhage and led to exsanguination of all the pigs (n = 6) within 10 to 15 minutes of the injury. Chitosan dressing produced initial hemostasis in five of seven pigs. However, the dressings failed to maintain hemostasis for more than 1.6 hours (range, 28-102 minutes), resulting in secondary bleeding and death of the animals. Fibrin sealant dressing produced initial hemostasis in all the pigs (n = 6) and maintained hemostasis in five cases, with one failure at 2.2 hours. These pigs resumed normal activities and lived for the 96-hour experiment duration. Computed tomographic images and histologic sections of the aortas from surviving fibrin sealant dressing-treated animals showed formation of pseudoaneurysms and early granulation tissue at the aortotomy site. The posttreatment blood loss, duration of hemostasis, and survival time were significantly different in the fibrin sealant dressing group than the chitosan dressing and army field dressing groups. CONCLUSION: Both chitosan dressing and fibrin sealant dressing stopped initial arterial bleeding that could not be controlled by the standard army field dressing. However, although the fibrin sealant dressing secured hemostasis for up to 4 days, the chitosan dressing consistently failed within 2 hours after application. There may be a risk of rebleeding for high-pressure arterial wounds treated with chitosan dressings, particularly in situations where definitive care is delayed substantially.     

Central renal stab wounds: treatment with augmented fibrin sealant in a porcine model

PURPOSE: We determined whether fibrin sealant augmented by an absorbable bolster could salvage kidneys with major, centrally located stab wounds. MATERIALS AND METHODS: A grade 4 renal injury was created in 16 commercial swine via a 1.5 cm sagittal, centrally located, through-and-through right renal laceration. Animals were randomized to 1 of 4 treatment arms, including control groups that received conventional renal capsule suture repair with an absorbable gelatin sponge bolster (3 in group 1) or a microfibrillar collagen sheet (3 in group 2) and experimental groups that received sutureless treatment entailing fibrin sealant instillation into the knife tract augmented by an external gelatin sponge (5 in group 3) or an external microfibrillar collagen sheet (5 in group 4). Arterial occlusion was not performed. Blood loss and time to hemostasis were recorded. Abdominal computerized tomography was performed at 1 week and necropsy was done at 6 weeks. RESULTS: Renal reconstruction with fibrin sealant resulted in significantly lower blood loss (62 vs 155 ml, p <0.05) and time to hemostasis (3.5 vs 6.5 minutes, p <0.05) than in the conventional suture groups. There was no radiographic or gross evidence of significant postoperative bleeding, urinoma formation or abnormal tissue healing in the recovery period. Gelatin sponge and collagen sheet demonstrated similar hemostatic efficacy. CONCLUSIONS: In this porcine renal trauma model fibrin sealant augmented by absorbable gelatin sponge or a microfibrillar collagen sheet effectively promoted hemostasis and renal salvage. Because of its safety, ease of use and efficiency, fibrin sealant appears to be an appropriate adjunct for managing challenging renal injuries.     

Fibrin sealant treatment of splenic injury during open and laparoscopic left radical nephrectomy

PURPOSE: We describe the use of fibrin sealant for rapid and definitive hemostasis of splenic injuries incurred during open and laparoscopic left nephrectomy. MATERIALS AND METHODS: In 2 patients undergoing left nephrectomy for a suspicious renal mass splenic laceration occurred during mobilization of the colonic splenic flexure at open nephrectomy and laparoscopic upper pole dissection, respectively. Fibrin sealant was applied topically in each case. RESULTS: In each patient fibrin sealant achieved immediate hemostasis and each recovered without further splenic bleeding. CONCLUSIONS: The topical application of fibrin sealant safely, rapidly and reliably achieves definitive hemostasis of splenic injuries. It is simple to use in the open and laparoscopic approaches.     

Current applications of fibrin sealant in urologic surgery

Biosurgical preparations designed to promote surgical hemostasis and tissue adhesion are being increasingly employed across all surgical disciplines. Fibrin sealant is the most widely studied and utilized biosurgical adjunct in urology. Complex reconstructive, oncologic, and laparoscopic genitourinary procedures are those most appropriate for sealant use. This article details the diverse urologic applications of fibrin sealant in the management of genitourinary injuries, surgery, and complications.     

Bleeding from the sternal marrow can be stopped using vivostat patient-derived fibrin sealant

BACKGROUND: Median sternotomy is the most important method of access to the heart. Bleeding from the sternal marrow may become significant, especially in elderly patients. Vivostat (ConvaTec, a Bristol-Myers Squibb Company, Skillman, NJ) patient-derived fibrin sealant is biocompatible and easily applied to the sternal marrow using the Vivostat Spraypen applicator. METHODS: Thirty patients undergoing elective cardiac operation were randomized to receive Vivostat fibrin sealant applied to either the right or left side of the sternum immediately after median sternotomy, with the untreated side serving as control. RESULTS: The average time to hemostasis was 43 seconds after treatment with Vivostat and 180 seconds on the control sides (p<0.001). At the end of the operation, complete hemostasis was observed on 24 of 30 sides treated with Vivostat compared with on 4 of 30 of the control sides (p<0.001). The average volume of sealant used to cover one side of the sternum was 0.9 mL. CONCLUSIONS: Vivostat patient-derived fibrin sealant is a biocompatible alternative to bone wax, with the results of this study showing that it provides effective control of bleeding after median sternotomy.     

Partial nephrectomy with fibrin glue repair: measurement of vascular and pelvicaliceal hydrodynamic bond integrity in a live and abbatoir porcine model

PURPOSE: Some of the challenges during partial nephrectomy include control of bleeding and repair of the pelvicaliceal system. Fibrin tissue sealants have recently been used to achieve hemostasis and collecting system closure in open and laparoscopic partial nephrectomy. However, there exist little data regarding the intrinsic strength of the bond, especially when applied to the vasculature and the urinary collecting system of the transected kidney. We examined the hydrodynamic bond integrity of a commercially available fibrin tissue sealant in a live porcine animal model undergoing partial nephrectomy. MATERIALS AND METHODS: Open partial nephrectomy was performed in 19 porcine renal units. Collecting system entry was confirmed by methylene blue instillation into the proximal ureter. Fibrin tissue sealant was used to repair 16 renal units, that is 8 kidneys hardened in vivo for 10 minutes and 8 hardened in vivo for 60 minutes. In an additional 3 renal units monopolar electrocautery was used to achieve hemostasis (no fibrin glue used). The strength of vasculature repair was performed by infusing saline into the renal artery (renal vein ligated) and measuring pressure at bond rupture. Similarly the integrity of pelvicaliceal repair was evaluated by retrograde infusion of saline into the collecting system via the proximal ureter and measurement of pressure at bond rupture. RESULTS: Fibrin tissue sealant was successful in achieving prompt hemostasis and it was subjectively superior to cautery alone with regard to bleeding control. Mean renal vascular and pelvicaliceal burst pressure for fibrin sealant treated kidneys was 378 (median 420) and 166 mm Hg (median 170), respectively. There was no significant difference in 10 vs 60-minute hardening times in treated kidneys. In comparison, vascular and pelvicaliceal burst pressure for nontreated (cautery alone) kidneys was 230 (median 220) and 87 mm Hg (median 90), respectively. CONCLUSIONS: Commercially available fibrin tissue sealants can provide supraphysiological renal parenchyma and collecting system sealing pressures after partial nephrectomy. This information supports the potential use of fibrin sealants during open and laparoscopic partial nephrectomy.